Hostname: page-component-54dcc4c588-gwv8j Total loading time: 0 Render date: 2025-10-09T13:13:30.775Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy of Topiramate

Published online by Cambridge University Press:  18 September 2015

J. Bruni
J. Bruni*
Affiliation:
Division of Neurology, Wellesley Central Hospital, University of Toronto, Toronto
*
The Wellesley Central Hospital, 318JB-160 Wellesley Street East, Toronto, Ontario, Canada M4Y 1J3
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

In controlled clinical trials, topiramate (TopamaxR) has demonstrated efficacy in refractory patients with complex partial seizures and secondarily generalized tonic-clonic seizures. Approximately 45 percent of 534 patients had a ≥ 50 percent reduction in seizure frequency. Limited open label trials have shown that topiramate has broad spectrum activity and may be effective in patients with primary generalized epilepsies. The efficacy of topiramate compares very favourably with the efficacy of other new antiepileptic drugs recently introduced.

Information

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 25 , Issue S3 , August 1998 , pp. S6 - S7
Copyright
Copyright © Canadian Neurological Sciences Federation 1998

References

REFERENCES

1.Faught, E, Wilder, BJ, Ramsay, RE, Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily doses. Neurology 1996; 46: 1684–1690.CrossRefGoogle Scholar
2.Privitera, M, Fineham, R, Penry, J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages. Neurology 1996; 46: 1678–1683.CrossRefGoogle Scholar
3.Chauvel, Tassinari C, Chadkiewicz, P, et al. Double-blind placebocontrolled trial of topiramate (600 mg/day) as add-on therapy in patients with refractory partial epilepsy. Epilepsia 1995; 36: (Suppl.3): 150.Google Scholar
4.Tassinari, CA, Michelucci, R, Chauvel, P, et al. Double-blind, placebo- controlled trial of topiramate (600 mg daily) for the treatment of refractory epilepsy. Epilepsia 1996; 37: 763–768.CrossRefGoogle Scholar
5.Sharief, M, Viteri, C, Ben-Menachen, E, et al. Double-blind placebocontrolled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996; 25: 217–224.CrossRefGoogle ScholarPubMed
6.Viteri, C, Martinez-Lage, J, Ben-Menachen, E, et al. Double-blind, placebo-controlled trial of 400 mg/day topiramate as add-on therapy in patients with refractory partial epilepsy. Epilepsia 1995; 36: (Suppl.3): 149.Google Scholar
7.Ben-Menachen, E, Henrikson, E, Dam, M, et al. Double-blind, placebo- controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996; 37 539–543.CrossRefGoogle Scholar
8.Reife, RA, Pledger, GW. Topiramate as adjunctive therapy in refractory partial epilepsy. Pooled analysis of data from five double-blind, placebo-controlled trials. Epilepsia 1997; 38 (Suppl.1): 31–37.CrossRefGoogle ScholarPubMed
9.Rosenfeld, WE, Sachdeo, RC, Faught, RE, et al. Long-term experience with topiramate as adjunctive therapy and as monotherapy in patients with partial onset seizures: retrospective survey of open-label treatment. Epilepsia 1997; 38 (Suppl.1): 34–36.CrossRefGoogle ScholarPubMed
10.Biton, V. Preliminary open-label experience with topiramate in primary generalized seizures. Epilepsia 1997; 38 (Suppl.1): 42–44.CrossRefGoogle ScholarPubMed
11.Sachdeo, SK, Sachdeo, RC, Reife, RA, Topiramate doubleblind trial as monotherapy. Epilepsia 1995; 36 (Suppl.4): 33.Google Scholar
12.Guberman, A, Couture, M, Bruni, J, et al. Long-term open label study of topiramate: the Canadian Experience. Can J Neurol Sci 1996; 23 (Suppl.1): 527.Google Scholar
13.Marson, AG, Kadir, ZA, Chadwik, DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996; 313: 1169–1174.CrossRefGoogle ScholarPubMed
14.Schneiderman, JH. Topiramate. Pharmacokinetics and pharmacodynamics. Can J Neurol Sci 1998; 25:S3-S5.CrossRefGoogle ScholarPubMed